We are live on ! Find out more
VYNT

Vyant Bio

Delisted

VYNT was delisted on the 12th of May, 2023.

26 hedge funds and large institutions have $8.36M invested in Vyant Bio in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.54% less ownership

Funds ownership: 16.2% → 15.65% (-0.54%)

7% less funds holding

Funds holding: 28 → 26 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

40% less capital inflows, than outflows

Capital inflows: $625K | Capital outflows: $1.05M

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

Holders
26
Holders Change
-2
Holders Change %
-7.14%
% of All Funds
0.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
5
Reduced
11
Closed
5
Calls
$368K
Puts
–
Net Calls
+$368K
Net Calls Change
-$51K

VYNT Hedge Fund Activity: Q3 2017 in Review

26 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio (VYNT) for Q3 2017, worth a combined $8.36M — down 34% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of VYNT and 3 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 5 added.

The largest buyer was UBS Group, adding an estimated $256K. The largest seller was EAM Investors, exiting entirely with an estimated $422K sold.

  • 26 institutional investors held Vyant Bio (VYNT) as of Q3 2017, down from 28 in Q2 2017.
  • Funds reported $8.36M of Vyant Bio stock for Q3 2017, down 34% quarter-over-quarter.
  • 3 funds opened new Vyant Bio positions in Q3 2017 and 5 closed out, a net change of -2 holders.
  • The largest Vyant Bio buyer in Q3 2017 was UBS Group, an estimated $256K added.
  • The largest Vyant Bio seller in Q3 2017 was EAM Investors, an estimated $422K sold.

Based on aggregated 13F filings for Q3 2017.